Literature DB >> 7526102

Inhibition of platelet activity by S-nitrosoglutathione during coronary angioplasty.

E J Langford1, A S Brown, R J Wainwright, A J de Belder, M R Thomas, R E Smith, M W Radomski, J F Martin, S Moncada.   

Abstract

Platelet activation is associated with acute vessel occlusion and chronic restenosis after percutaneous transluminal coronary angioplasty (PTCA). Organic nitrates, which act by releasing the vasodilator and anti-platelet agent nitric oxide (NO), have a predominantly vasodilator action and cause hypotension at doses required to inhibit platelet activation. S-nitrosoglutathione (GSNO) is an NO donor with a preferential action on platelets. We investigated platelet activation in patients undergoing PTCA and the effect of GSNO. Blood was sampled from the coronary sinus to measure platelet surface expression of P-selectin and glycoprotein IIb/IIIa as indices of platelet activation. In 7 control patients, PTCA caused a rise in platelet surface expression of P-selectin and glycoprotein IIb/IIIa, which was maximal 5 minutes after PTCA, indicating increased platelet activation despite treatment with aspirin, glyceryl trinitrate, and heparin. 6 patients received an intracoronary infusion of GSNO, starting 10 min before PTCA. GSNO significantly inhibited the PTCA-induced increase in platelet surface expression of P-selectin and glycoprotein IIb/IIIa without altering blood pressure. These findings show that platelets are activated following PTCA and that GSNO can prevent this activation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7526102     DOI: 10.1016/s0140-6736(94)90287-9

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  34 in total

Review 1.  Nitric oxide: discovery and impact on clinical medicine.

Authors:  S Moncada
Journal:  J R Soc Med       Date:  1999-04       Impact factor: 5.344

2.  Inhibition of human platelet aggregation by a novel S-nitrosothiol is abolished by haemoglobin and red blood cells in vitro: implications for anti-thrombotic therapy.

Authors:  I L Megson; N Sogo; F A Mazzei; A R Butler; J C Walton; D J Webb
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

3.  Antiinflammatory activity of soluble guanylate cyclase: cGMP-dependent down-regulation of P-selectin expression and leukocyte recruitment.

Authors:  Amrita Ahluwalia; Paul Foster; Ramona S Scotland; Peter G McLean; Anthony Mathur; Mauro Perretti; Salvador Moncada; Adrian J Hobbs
Journal:  Proc Natl Acad Sci U S A       Date:  2004-01-23       Impact factor: 11.205

4.  S-nitrosoglutathione reduces tau hyper-phosphorylation and provides neuroprotection in rat model of chronic cerebral hypoperfusion.

Authors:  Je-Seong Won; Balasubramaniam Annamalai; Seungho Choi; Inderjit Singh; Avtar K Singh
Journal:  Brain Res       Date:  2015-08-10       Impact factor: 3.252

5.  Neuroprotective strategies in Parkinson's disease: protection against progressive nigral damage induced by free radicals.

Authors:  C C Chiueh; T Andoh; A R Lai; E Lai; G Krishna
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

Review 6.  Recent developments in nitric oxide donor drugs.

Authors:  M R Miller; I L Megson
Journal:  Br J Pharmacol       Date:  2007-04-02       Impact factor: 8.739

7.  Stöber Synthesis of Nitric Oxide-Releasing S-Nitrosothiol-Modified Silica Particles.

Authors:  Daniel A Riccio; Julia L Nugent; Mark H Schoenfisch
Journal:  Chem Mater       Date:  2011-04-12       Impact factor: 9.811

Review 8.  S-Nitrosothiol biology and therapeutic potential in metabolic disease.

Authors:  Christopher G Kevil; Rakesh P Patel
Journal:  Curr Opin Investig Drugs       Date:  2010-10

9.  The effect of nitric oxide on glucose metabolism.

Authors:  Dalip Ragoobirsingh; Donovan McGrowder; Tara Dasgupta; Paul Brown
Journal:  Mol Cell Biochem       Date:  2004-08       Impact factor: 3.396

10.  Protective role of S-nitrosoglutathione (GSNO) against cognitive impairment in rat model of chronic cerebral hypoperfusion.

Authors:  Je-Seong Won; Jinsu Kim; Balasubramaniam Annamalai; Anandakumar Shunmugavel; Inderjit Singh; Avtar K Singh
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.